StockData
Erasca, Inc. logo

Erasca, Inc. (ERAS) stock

ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$13.61−0.61 (-4.29%)

Close on Nov 20, 2026Market cap $4.76BP/E –Yield 0.00%

Erasca free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Erasca's free cash flow for the twelve months ending Jun 30, 2026 was -$98.08M. For fiscal 2025 it was -$95.58M. The highest annual figure on record is -$33.63M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$95.58M–
FY2024Dec 31, 2024-$109.48M–
FY2023Dec 31, 2023-$102.99M–
FY2022Dec 31, 2022-$117.82M–
FY2021Dec 31, 2021-$90.81M–
FY2020Dec 31, 2020-$33.63M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$27.28M–
Q1 FY2026Mar 31, 2026-$27.42M–
Q4 FY2025Dec 31, 2025-$21.72M–
Q3 FY2025Sep 30, 2025-$21.66M–
Q2 FY2025Jun 30, 2025-$20.56M–
Q1 FY2025Mar 31, 2025-$31.64M–
Q4 FY2024Dec 31, 2024-$24.56M–
Q3 FY2024Sep 30, 2024-$22.42M–
Q2 FY2024Jun 30, 2024-$29.20M–
Q1 FY2024Mar 31, 2024-$33.29M–
Q4 FY2023Dec 31, 2023-$24.87M–
Q3 FY2023Sep 30, 2023-$24.36M–
Q2 FY2023Jun 30, 2023-$26.20M–
Q1 FY2023Mar 31, 2023-$27.56M–
Q4 FY2022Dec 31, 2022-$27.24M–
Q3 FY2022Sep 30, 2022-$25.74M–
Q2 FY2022Jun 30, 2022-$31.70M–
Q1 FY2022Mar 31, 2022-$33.14M–
Q4 FY2021Dec 31, 2021-$28.31M–
Q3 FY2021Sep 30, 2021-$27.89M–
Q2 FY2021Jun 30, 2021-$18.81M–
Q1 FY2021Mar 31, 2021-$15.79M–
Q4 FY2020Dec 31, 2020-$13.12M–
Q3 FY2020Sep 30, 2020-$7.63M–

More Erasca figures

See a number that looks wrong?